Get the Stockscreener App
1.41
1.40%
-0.02
Omniab Inc stock is traded at $1.41, with a volume of 312.07K.
It is down -1.40% in the last 24 hours and down -22.95% over the past month.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
See More
Previous Close:
$1.43
Open:
$1.43
24h Volume:
312.07K
Relative Volume:
0.34
Market Cap:
$172.50M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-2.7756
EPS:
-0.508
Net Cash Flow:
$703.00K
1W Performance:
-9.03%
1M Performance:
-22.95%
6M Performance:
-64.03%
1Y Performance:
-67.95%
1-Day Range:
$1.36
$1.45
1-Week Range:
$1.36
$1.63
52-Week Range:
$1.35
$4.96
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.41 | 185.95M | 34.16M | -50.62M | 703.00K | -0.508 |
|
ONC
Beigene Ltd Adr
|
238.63 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.74 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.28 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.06 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
OmniAb’s SWOT analysis: antibody discovery firm’s stock faces growth opportunities amid market challenges - Investing.com Canada
OmniAb Inc (NASDAQ: OABI) Could Pass $4 In One Year Stock Forecast - Stocksregister
Insider Spends US$94k Buying More Shares In OmniAb - simplywall.st
Chairman of OmniAb Picks Up 3.0% More Stock - Yahoo Finance
51,159 Shares in OmniAb, Inc. (NASDAQ:OABI) Purchased by Balyasny Asset Management L.P. - Defense World
Price T Rowe Associates Inc. MD Has $136,000 Stock Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Leerink Partnrs Has Bullish Forecast for OmniAb Q2 Earnings - Defense World
Insider Buying: Jennifer Cochran Acquires 30,000 Shares of OmniA - GuruFocus
Director Makes Bold Move with Major OmniAb Stock Purchase - TipRanks
Director’s Bold Move: A Major Investment in OmniAb Stock - TipRanks
Insider Buying: John Higgins Acquires 65,000 Shares of OmniAb In - GuruFocus
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit - marketscreener.com
Hsbc Holdings PLC Makes New Investment in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb’s (OABI) “Buy” Rating Reaffirmed at Benchmark - Defense World
OmniAb: Too Much Risk, Not Enough Reward (NASDAQ:OABI) - Seeking Alpha
OmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call Transcript - MSN
OmniAb : May 2025 Corporate Overview - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88 - simplywall.st
Dimensional Fund Advisors LP Increases Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
RBC Capital Remains a Buy on OmniAb (OABI) - The Globe and Mail
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates - MSN
OmniAb’s Earnings Call: Growth Amid Challenges - TipRanks
OmniAb Introduces the xPloration® Partner Access Program - BioSpace
OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls By Investing.com - Investing.com South Africa
Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
OmniAb Introduces the xPloration(R) Partner Access Program - marketscreener.com
OmniAb Reports Steady Growth in Q1 2025 - TipRanks
OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls - Investing.com Nigeria
OmniAb, Inc. (NASDAQ:OABI) Shares Acquired by Barclays PLC - Defense World
OmniAb Inc (OABI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Wells Fargo & Company MN Purchases 12,278 Shares of OmniAb, Inc. (NASDAQ:OABI) - Defense World
Earnings call transcript: OmniAb’s Q1 2025 shows revenue growth and cost control - Investing.com
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
OmniAb Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
OmniAb to Participate in Two Investor Conferences in November - marketscreener.com
Ratio Revelations: OmniAb Inc (OABI)’s Financial Metrics in the Spotlight - DWinneX
Veraxa and OmniAb to develop bispecific ADC tumour programme - Yahoo Finance
OmniAb, Veraxa Biotech Partner on Solid Tumor Drug Discovery Program - marketscreener.com
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - The Manila Times
VERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid Tumors - Nasdaq
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - GlobeNewswire Inc.
VERAXA Biotech Enters Co-Discovery Alliance with OmniAb - Contract Pharma
OmniAb Inc [OABI] Records 200-Day SMA of $3.6405 - knoxdaily.com
A stock that deserves closer examination: OmniAb Inc (OABI) - uspostnews.com
OmniAb to Participate in Five Upcoming Investor Conferences - marketscreener.com
OmniAb Inc (OABI) Stock: Navigating Drops and Gains - investchronicle.com
Legal & General Group Plc Decreases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb Inc (OABI) can make a big difference with a little luck - Sete News
Ratio Examination: OmniAb Inc (OABI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
RBC Capital Mkts initates OmniAb Inc (OABI) stock to an Outperform - knoxdaily.com
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
8.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):